Mitochondrial-Targeted Peptide Modulators of Delta Protein Kinase C Interaction with the d-subunit of F1Fo ATP Synthase/ATPase as Therapeutics Against Cardiac Injury


Current State of the Art: 

Current clinical therapy for heart attack victims focuses on the rapid restoration of blood flow by thrombolysis, angioplasty, stenting and when appropriate surgical coronary artery bypass grafts.


Problems with the Current Art:

The majority of cardiac cell death associated with a heart attack actually occurs during the early phases of reperfusion when blood flow is restored. Cardioprotective agents that minimize cell death during reperfusion therapy are desperately needed and would greatly improve the outcomes of these patients.


Advantages of the Novel Invention:

One important event contributing to cardiac injury during reperfusion therapy is an excessive inhibition of the F1Fo ATP synthase by δPKC. Enhancing the return of aerobic ATP production following cardiac ischemia reperfusion would dramatically improve the survival and functionality of the heart. d-subunit F1Fo-derived peptides interfere with or enhance δPKC modulation of F1Fo ATP synthase or ATPase activities. These peptides are first-in-class drugs that potentially protect the myocardium by facilitating a more rapid return of aerobic ATP synthesis following an ischemia reperfusion or hyperglycemic insult. They have potential as solo or adjunctive therapy with other cardio-protective drugs.


Patent Status: PCT Filed


Inventors: John Johnson, Ph.D; Tiffany Tuyen Nguyen; Mourad Ogbi;


Case Number: GHSU 2009-042

Patent Information:
For Information, Contact:
Augusta University
John Johnson
Tiffany Tuyen Nguyen
Mourad Ogbi
Heart Attack
© 2024. All Rights Reserved. Powered by Inteum